The Global Microcarrier Market revenue has been estimated at USD 1,300.0 million in 2021 and is projected to grow at a CAGR of 8.3% during the forecast period. The growth of the global market is expected to be driven by the rising demand for cell-based vaccines and increasing R &D funding for cell and gene research by pharmaceutical and biotechnology companies. Technological advancement is another key factor that has been fueling the growth of the global market.
Microcarriers are basically small polymeric beads composed of a solid matrix that provide an attachment surface to the suspended cell culture. The diameter of a microcarrier is usually in the range of 100- 300μm. Microcarriers are basically a support matrix, and their main function is to promote the growth of the adherent cells in bioreactors in the production of vaccines and biologics.
Some of the important advantages offered by microcarriers include the ability to regulate cell growth conditions precisely in sophisticated bioreactors, reduction in the number of incubators required, and ease of scale-up. Due to such advantages, demand for microcarriers in the pharmaceutical and biotechnology industries has been growing, which in turn, will provide a major stimulus to market growth.
The growth of the microcarrier market will be propelled by the increasing demand for stem cell therapy and the growing cancer burden. Further, the risk of virus outbreaks has grown substantially in recent times, mainly due to rising population, increasing contact between humans and animals, and climate change. This, in turn, is expected to increase the demand for vaccines and thereby provide a major impetus to the global market for microcarriers. For example, the recent coronavirus or COVID-19 outbreak has increased the demand for vaccines, prompting major pharmaceutical companies to scale up their R&D efforts for vaccine development. As cell culture has become an important part of vaccine development, this has given a major thrust to the global microcarrier market.
Cell culture is a far more efficient method with shortened lead time and is also suitable for large-scale vaccine production. Therefore, it is preferred over the earlier method of harvesting viruses in chicken eggs, which was a time-consuming process. Further, cell-based vaccines have been found to be more effective, safer, and more efficacious than egg-based vaccines, as per the results of several clinical trials. Hence, demand for cell-based vaccines has been increasing, thereby driving the demand for microcarriers for large-scale commercial vaccine production.
Apart from these, the growth of the global microcarrier market will be driven by factors such as increasing incidence of diseases requiring cell therapy, technological advancements in microcarrier development, and growing R &D funding by biopharmaceutical companies and research institutes. Further, increasing demand for monoclonal antibodies due to the rising popularity of targeted treatment for cancer and other chronic disorders like autoimmune diseases will provide opportunities for market growth.
On the other hand, microcarriers are mainly used in stem cell biology, which involves extensive R&D on new therapies and requires equipment, reagents, and media of the highest quality. As a result, the cost of cell biology research has increased significantly in recent times. Further, the need to comply with regulatory guidelines has added to the cost of cell biology research. The high cost of stem cell biology research can be a major restraint for the microcarrier market.
Overview:The Global Microcarrier Market is anticipated to hold a market value of USD 1.18 billion with an estimated CAGR of 5.9% during the forecast period.
The microcarrier system provides high cell yields without having to resort to bulky equipment and tedious methodology.
The rise in the use of microcarrier technology for various cell-based applications, coupled with the advantages of the microcarrier system such as its support for high yield of cells, facilitation of polarization and differentiation of cells, and lower risk of contamination are expected to drive the growth of the market during the forecast period.
For instance, in March 2018, Danaher announced that it has entered into a definitive agreement to acquire Integrated DNA Technologies, a privately-held provider of high-value consumables for genomics applications in next generation sequencing, synthetic biology, molecular biology, gene editing and molecular diagnostics.Segmentation:The global microcarriers market can be assessed on the findings of segments like product type, application, and end-user.
MRFR’s report provides a detailed glimpse into the market that can be shared to make a better assessment of the market.
Competitive Landscape:Companies that have been included in the global market for microcarriers are GENERAL ELECTRIC COMPANY, Thermo Fisher Scientific Inc., Sartorius AG, Corning Incorporated, Becton, Dickinson and Company, Danaher, Merck KGaA, HiMedia Laboratories, Eppendorf AG, Lonza, and others.
COVID-19 Impact Analysis on Microcarrier Beads Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2020-2027.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the microcarrier beads market include Thermo Fisher Scientific Inc., GENERAL ELECTRIC COMPANY, Corning Incorporated, Sartorius AG, Danaher, Merck KGaA, Becton Dickinson and Company, Eppendorf AG, HiMedia Laboratories, and Lonza.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Microcarrier Beads Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/microcarrier-beads-market/download-sampleMarket DynamicsBooming vaccine manufacturing, cell therapy, and biologics manufacturing worldwide are thriving demand for microcarrier beads.
Vaccine manufacturers are increasingly making use of microcarriers beads over other technologies as it can significantly reduce process complexity and labor intensity even in the large-scale culture process.
However, economic uncertainties, trade barriers, and shortage of supply are hindering the market growth.The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis.
The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.
It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.
Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.
Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.
Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.
Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.
Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.
Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.
Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.
